Promising Results for Enfortumab Vedotin in Neoadjuvant Treatment of Cisplatin-Ineligible Muscle-Invasive Bladder Cancer
This MEDtalk provides background information about muscle-invasive bladder cancer, the standard treatment approaches, and the challenges of cisplatin-ineligible patients. Dr. Srikala Sridhar
describes the study design and the results of Study EV-103 Cohort L, including the pathological complete response rate and safety profile of the treatment with enfortumab vedotin in the neoadjuvant setting.
Få tillgång
Om du är läkare, sjuksköterska eller annan vårdpersonal kan du komma åt hela artikeln genom att skapa en profil på BestPractice Nordic.
- Få tillgång
- Om du redan har en profil: Logga in